IP Library › Granted Patent US 11,104,734
Granted Patent B2
US 11,104,734 · App. 16/146,925 · Granted Aug 31, 2021

Anti-PD-1 monoclonal antibody

Inventors: Yu Xia (Guangdong, CN); Baiyong Li (Guangdong, CN); Zhongmin Maxwell Wang (Guangdong, CN); Faming Zhang (Hubei, CN); Gan Xi (Hubei, CN); Ying Huang (Hubei, CN)
Assignees: Akeso Biopharma, Inc.; Taizhou Hanzhong Biopharmaceutics, Inc.
C07K16/2818C07K2317/24C07K2317/56C07K2317/565C07K2317/74C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,104,734
App. No.
16/146,925
Granted
Aug 31, 2021
Kind
B2
Abstract

Proposed is an anti-PD-1 monoclonal antibody or an antigen binding fragment thereof, comprising a heavy chain variable region having at least one of the amino acid sequences listed below: (1) the amino acid sequence shown in SEQ ID NO: 1; (2) the amino acid sequence shown in SEQ ID NO: 3; (3) the amino acid sequence shown in SEQ ID NO: 5; and (4) an amino acid sequence having more than one conservative amino acid mutation compared with (1)-(3).

Claims (13)

1. An antibody or antigen-binding fragment thereof, comprising:

a heavy chain CDR1 comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:14), CDR2 comprising the amino acid sequence of ISGGGRDT (SEQ ID NO:15), and CDR3 comprising the amino acid sequence of ARQKGEAWFAY (SEQ ID NO:16); and

a light chain CDR1 comprising the amino acid sequence of ESVDNYGISF (SEQ ID NO:17), CDR2 comprising the amino acid sequence of AAS (SEQ ID NO:18), and CDR3 comprising the amino acid sequence of QQSKEVPWT (SEQ ID NO:19).

2. The antibody or antigen-binding fragment thereof according to claim 1 , comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, 3, or 5.

3. The antibody or antigen-binding fragment thereof according to claim 1 , comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2, 4, or 6.

4. The antibody or antigen-binding fragment thereof according to claim 1 , comprising:

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2;

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4; or

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 5 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6.

5. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof is humanized.

6. The antibody or antigen-binding fragment thereof according to claim 1 , comprising:

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:3, and

a light chain variable region comprising the amino acid sequence of SEQ ID NO:4.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: XIA, YU; LI, BAIYONG; WANG, ZHONGMIN MAXWELL; ZHANG, FAMING; XI, GAN; HUANG, YING
To: AKESO BIOPHARMA, INC.; TAIZHOU HANZHONG BIOPHARMACEUTICS, INC.
Reel/Frame 047032/0831 →
Priority Claims (1)
CN 201610207741.6 · Apr 1, 2016 · national
Continuity (2)
Continuation PCTCN2016103814 · Oct 28, 2016
Related Publication 20190040138A1 · Feb 7, 2019
Cited By (1)
US 12,673,997